Editorial: The Roles of Checkpoint Inhibitors in Inflammatory Diseases
Overview
Overview
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Patil N, Guo Y, Luan L, Sherwood E
. Targeting Immune Cell Checkpoints during Sepsis. Int J Mol Sci. 2017; 18(11).
PMC: 5713381.
DOI: 10.3390/ijms18112413.
View
2.
Wakeley M, Gray C, Monaghan S, Heffernan D, Ayala A
. Check Point Inhibitors and Their Role in Immunosuppression in Sepsis. Crit Care Clin. 2019; 36(1):69-88.
PMC: 6863093.
DOI: 10.1016/j.ccc.2019.08.006.
View
3.
Keir M, Butte M, Freeman G, Sharpe A
. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008; 26:677-704.
PMC: 10637733.
DOI: 10.1146/annurev.immunol.26.021607.090331.
View
4.
Gillis A, Beil M, Halevi-Tobias K, van Heerden P, Sviri S, Agur Z
. Alleviation of exhaustion-induced immunosuppression and sepsis by immune checkpoint blockers sequentially administered with antibiotics-analysis of a new mathematical model. Intensive Care Med Exp. 2019; 7(1):32.
PMC: 6560115.
DOI: 10.1186/s40635-019-0260-3.
View
5.
Liu J, Chen Z, Li Y, Zhao W, Wu J, Zhang Z
. PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy. Front Pharmacol. 2021; 12:731798.
PMC: 8440961.
DOI: 10.3389/fphar.2021.731798.
View